Table 2.
The affinity of peptide analogs for CTR and AMY receptor ECDs.
| Figure and Receptor ECD |
Competitive sCT(22–32) Analog | N | pKI Mean ± SD |
Mean KI (nM) |
|---|---|---|---|---|
|
Figure 1d CTR ECD |
sCT(22–32) | 3 | 5.75 ± 0.10 | 1760 |
| sCT(22–32) N26D | 3 | 6.00 ± 0.03 1 | 1000 | |
| sCT(22–32) S29P | 3 | 6.46 ± 0.06 1,2 | 343 | |
| sCT(22–32) N26D/S29P | 3 | 6.50 ± 0.13 1,2 | 314 | |
|
Figure 2b CTR ECD |
sCT(22–32) N26D | 3 | 6.01 ± 0.01 | 980 |
| sCT(22–32) N26D/S29A | 3 | 6.36 ± 0.13 2 | 437 | |
| sCT(22–32) N26D/S29V | 3 | 6.23 ± 0.11 | 591 | |
|
Figure 3b CTR ECD |
sCT(22–32) N26D/S29P | 3 | 6.62 ± 0.15 | 239 |
| sCT(22–32) N26D/S29HYP | 3 | 5.50 ± 0.03 3 | 3180 | |
|
Figure 4b CTR ECD |
sCT(22–32) | 4 | 5.69 ± 0.09 | 2030 |
| sCT(22–32) P32HYP | 3 | 6.05 ± 0.04 1 | 887 | |
| sCT(22–32) N26D/S29P/P32HYP | 3 | 7.02 ± 0.12 1,4 | 95 | |
|
Figure 5e AMY receptor 1 ECD |
sCT(22–32) | 3 | 5.59 ± 0.18 | 2550 |
| sCT(22–32) P32HYP | 3 | 6.05 ± 0.03 1 | 887 | |
| sCT(22–32) N26D/S29P | 3 | 6.42 ± 0.08 1,4 | 381 | |
| sCT(22–32) N26D/S29P/P32HYP | 3 | 6.91 ± 0.15 1,3,4 | 124 | |
|
Figure 5f AMY receptor 2 ECD |
sCT(22–32) | 3 | 5.55 ± 0.11 | 2800 |
| sCT(22–32) P32HYP | 3 | 5.85 ± 0.10 1 | 1430 | |
| sCT(22–32) N26D/S29P | 3 | 6.33 ± 0.06 1,4 | 470 | |
| sCT(22–32) N26D/S29P/P32HYP | 3 | 6.47 ± 0.02 1,4 | 340 | |
|
Figure 5g AMY receptor 3 ECD |
sCT(22–32) | 3 | 5.59 ± 0.03 | 2560 |
| sCT(22–32) P32HYP | 3 | 6.00 ± 0.07 1 | 995 | |
| sCT(22–32) N26D/S29P | 3 | 6.48 ± 0.04 1,4 | 333 | |
| sCT(22–32) N26D/S29P/P32HYP | 3 | 6.93 ± 0.07 1,3,4 | 118 |
1 p < 0.05 compared to sCT(22–32). 2 p < 0.05 compared to sCT(22–32) N26D. 3 p < 0.05 compared to sCT(22–32) N26D/S29P. 4 p < 0.05 compared to sCT(22–32) P32HYP. ANOVA with Tukey’s multiple comparison test was used for statistical analysis except for Figure 3b where Student’s t-test was used. N indicates numbers of independent experiments. pKI indicates –log10[KI] (KI as molar concentration).